PDF(Pubmed)
Abstract：
To investigate the effectiveness and safety of gonadotropin-releasing hormone analogue (GnRHa) in combination with recombinant human growth hormone (rhGH) in girls with central precocious puberty (CPP).
Clinical data of 80 girls diagnosed with idiopathic central precocious puberty (ICPP) between January 2017 and June 2021 were retrospectively analyzed. Treatment strategy involved GnRHa alone (group A: n=34) and GnRHa+rhGH (group B: n=46). Children\'s heights (Ht), weights (Wt) and sex hormone levels were measured every 3 months after treatment and bone age (BA) every six months. Heights, growth velocity (GV), predicted adult height (PAH), weights, body mass index (BMI), sex hormone levels and bone age were compared between the two groups.
Children in group B showed greater height gain at the 12th, 24th and 30th months after treatment (p<0.05) than those in group A, had faster growth rates in the first and second year following treatment (p<0.05) and better PAH (p<0.05). No statistical differences in weight or BMI were found between the two groups before treatment or at any time after treatment (p>0.05). Levels of LH and FSH were lower in both groups after treatment with no statistical differences between groups (p>0.05). The gap between bone age and chronological age gradually decreased in both groups and no abnormal progression of bone age or other adverse side effects occurred.
The combination of GnRHa with rhGH produced better height gains than GnRHa alone for patients with CPP. The gonadal axis was suppressed and progression of bone age delayed with good safety and efficacy.
Clinical data of 80 girls diagnosed with idiopathic central precocious puberty (ICPP) between January 2017 and June 2021 were retrospectively analyzed. Treatment strategy involved GnRHa alone (group A: n=34) and GnRHa+rhGH (group B: n=46). Children\'s heights (Ht), weights (Wt) and sex hormone levels were measured every 3 months after treatment and bone age (BA) every six months. Heights, growth velocity (GV), predicted adult height (PAH), weights, body mass index (BMI), sex hormone levels and bone age were compared between the two groups.
Children in group B showed greater height gain at the 12th, 24th and 30th months after treatment (p<0.05) than those in group A, had faster growth rates in the first and second year following treatment (p<0.05) and better PAH (p<0.05). No statistical differences in weight or BMI were found between the two groups before treatment or at any time after treatment (p>0.05). Levels of LH and FSH were lower in both groups after treatment with no statistical differences between groups (p>0.05). The gap between bone age and chronological age gradually decreased in both groups and no abnormal progression of bone age or other adverse side effects occurred.
The combination of GnRHa with rhGH produced better height gains than GnRHa alone for patients with CPP. The gonadal axis was suppressed and progression of bone age delayed with good safety and efficacy.
摘要：
UNASSIGNED：目的研究促性腺激素释放激素类似物（GnRHa）与重组人生长激素（rhGH）联合应用于中枢性早熟（CPP）女孩的有效性和安全性。
UNASSIGNED：回顾性分析2017年1月至2021年6月间80例特发性中枢性性早熟（ICPP）女孩的临床资料。治疗策略包括单独GnRHa(A组:n=34)和GnRHa+rhGH(B组:n=46)。儿童身高（Ht），治疗后每3个月测量体重（Wt）和性激素水平，每6个月测量骨龄（BA）。高地,生长速度(GV)，预测成人身高（PAH），重量,体重指数（BMI），比较两组性激素水平和骨龄。
UNASSIGNED：B组儿童在第12位表现出更大的身高增长，治疗后第24个月和第30个月(p<0.05),在治疗后的第一年和第二年有更快的增长率（p<0.05）和更好的PAH（p<0.05）。两组治疗前或治疗后任何时间的体重或BMI均无统计学差异（p>0.05）。两组患者治疗后LH、FSH水平均较低,组间差异无统计学意义(p>0.05)。两组的骨龄和实际年龄之间的差距逐渐减小，并且没有发生骨龄异常进展或其他不良副作用。
UNASSIGNED：对于CPP患者，GnRHa与rhGH的组合比单独使用GnRHa产生更好的身高增长。性腺轴受到抑制，骨龄延迟，具有良好的安全性和有效性。
UNASSIGNED：回顾性分析2017年1月至2021年6月间80例特发性中枢性性早熟（ICPP）女孩的临床资料。治疗策略包括单独GnRHa(A组:n=34)和GnRHa+rhGH(B组:n=46)。儿童身高（Ht），治疗后每3个月测量体重（Wt）和性激素水平，每6个月测量骨龄（BA）。高地,生长速度(GV)，预测成人身高（PAH），重量,体重指数（BMI），比较两组性激素水平和骨龄。
UNASSIGNED：B组儿童在第12位表现出更大的身高增长，治疗后第24个月和第30个月(p<0.05),在治疗后的第一年和第二年有更快的增长率（p<0.05）和更好的PAH（p<0.05）。两组治疗前或治疗后任何时间的体重或BMI均无统计学差异（p>0.05）。两组患者治疗后LH、FSH水平均较低,组间差异无统计学意义(p>0.05)。两组的骨龄和实际年龄之间的差距逐渐减小，并且没有发生骨龄异常进展或其他不良副作用。
UNASSIGNED：对于CPP患者，GnRHa与rhGH的组合比单独使用GnRHa产生更好的身高增长。性腺轴受到抑制，骨龄延迟，具有良好的安全性和有效性。
